§ 522.313c Ceftiofur sodium.

Specifications.(a) Each milliliter of aqueous solution constituted from ceftiofur sodium powder contains 50 milligrams (mg) ceftiofur equivalents.

Sponsors.(b) See Nos. 017033 and 054771 in § 510.600(c) of this chapter.

Related tolerances.(c) See § 556.113 of this chapter.

Special considerations.(d) Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits extra-label use of this drug in cattle, swine, chickens, and turkeys for disease prevention purposes; at unapproved doses, frequencies, durations, or routes of administration; and in unapproved major food-producing species/production classes.

Conditions of useSwineAmount.(e) —(1) —(i) 3 to 5 mg per kilogram (/kg) body weight by intramuscular injection for 3 consecutive days.

Indications for use.Actinobacillus pleuropneumoniaePasteurella multocidaSalmonella choleraesuisStreptococcus suis.(ii) For treatment and control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with , , , and

Limitations.(iii) Treated pigs must not be slaughtered for 4 days following the last treatment.

CattleAmount.(2) —(i) 0.5 to 1.0 mg/lb body weight by intramuscular or subcutaneous injection for 3 days. Additional treatments may be given on days 4 and 5 for animals which do not show satisfactory response.

Indications for use.Mannheimia haemolytica, Pasteurella multocida,Histophilus somni.Fusobacterium necrophorumBacteroides melaninogenicus.(ii) For treatment of bovine respiratory disease (shipping fever, pneumonia) associated with and Also, for the treatment of acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with and

Limitations.(iii) Treated cattle must not be slaughtered for 4 days following the last treatment.

SheepAmount.(3) —(i) 0.5 to 1.0 mg/lb body weight by intramuscular injection for 3 days. Additional treatments may be given on days 4 and 5 for animals which do not show satisfactory response.

Indications for use.Mannheimia haemolyticaPasteurella multocida.(ii) For treatment of sheep respiratory disease (sheep pneumonia) associated with and

GoatsAmount.(4) —(i) 0.5 to 1.0 mg/lb body weight by intramuscular injection for 3 days. Additional treatments may be given on days 4 and 5 for animals which do not show satisfactory response.

Indications for use.Mannheimia haemolyticaPasteurella multocida.(ii) For treatment of caprine respiratory disease (goat pneumonia) associated with and

ChickensAmount.(5) —(i) 0.08 to 0.20 mg as a single subcutaneous injection in the neck.

Indications for use.Escherichia coli(ii) For control of early mortality associated with organisms susceptible to ceftiofur in day-old chicks.

TurkeysAmount.(6) —(i) 0.17 to 0.5 mg as a single subcutaneous injection in the neck.

Indications for use.E. coli(ii) For control of early mortality associated with organisms susceptible to ceftiofur in day-old poults.

HorsesAmount.(7) —(i) 2.2 to 4.4 mg/kg (1.0 to 2.0 mg/lb) body weight by intramuscular injection. Treatment should be repeated every 24 hours, continued for 48 hours after clinical signs have disappeared, and should not exceed 10 days. A maximum of 10 mL should be administered per injection site.

Indications for use.Streptococcus zooepidemicus.(ii) For treatment of respiratory infections in horses associated with

Limitations.(iii) Do not use in horses intended for human consumption.

DogsAmount.(8) —(i) 1.0 mg/lb (2.2 mg/kg) body weight by subcutaneous injection. Treatment should be repeated at 24-hour intervals for 5 to 14 days.

Indications for use.E. coliProteus mirabilis.(ii) For treatment of canine urinary tract infections associated with and

[53 FR 5369, Feb. 24, 1988, as amended at 55 FR 13768, Apr. 12, 1990; 56 FR 12119, Mar. 22, 1991; 57 FR 41862, Sept. 14, 1992; 59 FR 41666, Aug. 15, 1994; 59 FR 54518, Nov. 1, 1994; 60 FR 51719, Oct. 3, 1995; 61 FR 35130, July 5, 1996; 61 FR 66583, Dec. 18, 1996; 66 FR 21283, Apr. 30, 2001; 66 FR 32540, June 15, 2001; 69 FR 47362, Aug. 5, 2004. Redesignated and amended at 71 FR 39544, July 13, 2006; 74 FR 34236, July 15, 2009; 77 FR 29218, May 17, 2012; 79 FR 16185, Mar. 25, 2014; 79 FR 21127, Apr. 15, 2014; 82 FR 12169, Mar. 1, 2017; 89 FR 95103, Dec. 2, 2024]